India's mammoth biometrics project, Aadhaar, has been challenged as an expensive undertaking that risked duplicating ID schemes already in place. But a new study suggests that Aadhaar may be on track to reaching its goal of IDing unregistered low-income millions across rural India. A survey of 514,000 households show that 56 percent of Aadhaar enrollees did not have other forms of portable IDs. Lead author Arun Sundararajan from NYU's Stern business school predicts that 300 million Indians without any form of ID would have one by the end of 2012, if signups and enrollments continue in the coming months as expected. "What's important here is that we are not simply seeing people with pre-existing portable ID adding yet another one to their repertoire" Sundararajan said in the release. "Rather, millions of Indians who had no modern form of ID now have one, and this number is growing every month." A form of ID is required to open bank accounts, register for cell phones, and access any kind of government benefit scheme. As enrollment numbers grow--200 million Indians have been enrolled, 170 million have been issued IDs--the Aadhaar system is due to be piloted at banks in 50 districts in India.
HTC and Facebook may be building another phone together, DigiTimes has heard, to launch by Q3 this year. The Android device will have certain Facebook-specific features tucked in. It will be the third phone HTC is working on, after the ChaCha and Salsa. The partnership is an alignment of allies: As Samsung partners with Google for the Nexus series, HTC picks Facebook as a partner.
Facebook is offering Facebookers 6 months' worth of free antivirus software via a new partnership with security champs McAfee, Microsoft, Symantec, Sophos, and TrendMicro. Users can download protection from Facebook's new Antivirus Marketplace, and the antivirus protection won't be confined to user's Facebook pages, rather, the companies will squash web-wide threats. Facebook's massive popularity makes it a target for bad links and spam, something Facebook's been tackling through its partnership with companies like McAfee and Websense. Those security companies scan every link a Facebooker clicks on, and compare it with a "blacklist" of bad sites on their databases. A user is then warned about the site before they can click to proceed. Now, with the free antivirus downloads, it looks like Facebook's taking a broader approach to keeping the social network safe.
Google's just released a new resource for enterprises that are struggling to adapt their business models to address the new mobile technology revolution. In building the Mobile Playbook, Google says it spoke to "hundreds" of companies, and that they "understand that they need to invest in mobile to engage with their customers on this platform. The problem is, most don't know where to start." Hence the HTML5-based resource that Google's put together. It's accessible on tablets, of course, and Google has a vested interest in helping companies go mobile as it supplies the OS behind the majority of the world's smartphones, and also sells billions of mobile ads this way. Keen eyes will spot, however, that Google's example image is of an Apple iPad.
• Amgen (AMGN) Smacks Down $700 Million for Turkey Drugmaker More...
• GlaxoSmithKline (GSK) Insists it is the Best Owner for Human Genome Sciences, Inc. (HGSI) More...
• Targacept, Inc. (TRGT) to Cut 46% Of Workforce After Drug-Trial Setbacks More...
• Gene Ray, Founder of $2.6 Billion Titan Corporation (TTN), Invests in MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.)'s ERC Technology and Joins Advisory Board More...
• Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in Drug Discovery Collaboration More...
• AstraZeneca PLC (AZN) and The Medicines Company (MDCO) Announce Global Collaboration in Acute Ischemic Heart Disease More...
• AtheroNova Inc. (AHRO.OB) Signs Agreement for Development of Clinical Trial Supplies More...
• Integral Molecular, Inc. Announces Lipoparticle Distribution in Japan by Funakoshi Co. More...
• Johnson & Johnson (JNJ) CEO Under Fire for Big Bonuses Amid Scandals More...
• Novartis AG (NVS) Tries More Exec Level OTC Switches More...
• Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer More...
• Zyngenia Recruits David Parkinson, M.D., as Board Member, Clinical Advisory Board Head, and Interim Chief Medical Officer More...
• Threshold Pharmaceuticals, Inc. (THLD) Appoints Robert Simon as Senior Vice President of Regulatory Affairs More...
• Boehringer Ingelheim Corporation's 2011 Profit Jumps 66 Percent More...
• Amgen (AMGN) Posts Strong Drug Sales, Beats Estimates More...
• Amgen (AMGN)'s First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61More...
• Acura Pharmaceuticals, Inc. (ACUR) to Host First Quarter 2012 Financial Results Conference Call on May 2, 2012 More...
• Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Reports First Quarter 2012 Financial Results and Corporate Updates More...
• ViroPharma Incorporated (VPHM) Loses Bid for Order Blocking Generic Vancocin More...
• Icahn and Amylin Pharmaceuticals, Inc. (AMLN) Have May 10 Hearing for Proxy War More...
• Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc. More...
• Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction More...
• Pfizer Consumer Healthcare (PFE) Release: The Advil® Congestion Relief Project Visits St. Louis To Expand Building Space For More Access To Local Family Social Service Program More...
• Ipsen Pursues Its Development in the United States With the Opening of Its New Commercial Headquarters in New Jersey (NJ) More...
• Sanofi (France) (SAN.PA)'s Lemtrada Beats Rebif in MS Face-off More...
• Kythera Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat More...
• AVI BioPharma, Inc. (AVII) to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 American Academy of Neurology Annual Meeting More...
• Repligen Corporation (RGEN) Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy More...
• Ablynx Release: Nanobody for Alzheimer's Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials More...
• American Regent, Inc. Initiates Nationwide Voluntary Recall of Epinephrine Injection, USP, 1:1000, 1 mL Ampules Lot #1395 Due to Discoloration and Small Visible Particles More...
• Novartis AG (NVS) Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing's Disease More...
• Salix Pharmaceuticals, Ltd. (SLXP), Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 More...
• Fish Oil Could be Therapy for Periodontal Disease, University of South Australia Reveals More...
• Botox Ingredient Has Limited Effect on Headaches, Medical College of Wisconsin Study More...
• Does Fatty Food Impact Marital Stress? Ohio State University Medical Center Study More...
• Signs of Early DNA "Aging" in Abused Kids, Duke University Study More...
• Evaluating the First Drug to Show Improvement in Subtype of Autism, Mount Sinai School of Medicine Study More...
• VistaGen Therapeutics, Inc. Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity More...
• Lpath, Inc. Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab More...
• Metabolix, Inc. Awarded Two U.S. Patents for Technology to Produce Biobased Polymers and Industrial Chemicals More...
• BioLineRx Ltd. Announces Extension of Patent for BCM (BL-1040) by USPTO More...
• Marshall Edwards, Inc. (MSHL) Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer More...
• Novartis AG (NVS)'s Gilenya Given Final Approval by UK's Cost Agency More...
• PuraMed BioScience Continues to Build Awareness for LipiGesic(R) M Through Media Campaigns More...
• New Products from Abbott Laboratories (ABT)'s EAS(R) Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals More...
• GlaxoSmithKline (GSK) Insists it is the Best Owner for Human Genome Sciences, Inc. (HGSI) More...
• Targacept, Inc. (TRGT) to Cut 46% Of Workforce After Drug-Trial Setbacks More...
• Gene Ray, Founder of $2.6 Billion Titan Corporation (TTN), Invests in MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.)'s ERC Technology and Joins Advisory Board More...
• Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in Drug Discovery Collaboration More...
• AstraZeneca PLC (AZN) and The Medicines Company (MDCO) Announce Global Collaboration in Acute Ischemic Heart Disease More...
• AtheroNova Inc. (AHRO.OB) Signs Agreement for Development of Clinical Trial Supplies More...
• Integral Molecular, Inc. Announces Lipoparticle Distribution in Japan by Funakoshi Co. More...
• Johnson & Johnson (JNJ) CEO Under Fire for Big Bonuses Amid Scandals More...
• Novartis AG (NVS) Tries More Exec Level OTC Switches More...
• Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer More...
• Zyngenia Recruits David Parkinson, M.D., as Board Member, Clinical Advisory Board Head, and Interim Chief Medical Officer More...
• Threshold Pharmaceuticals, Inc. (THLD) Appoints Robert Simon as Senior Vice President of Regulatory Affairs More...
• Boehringer Ingelheim Corporation's 2011 Profit Jumps 66 Percent More...
• Amgen (AMGN) Posts Strong Drug Sales, Beats Estimates More...
• Amgen (AMGN)'s First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61More...
• Acura Pharmaceuticals, Inc. (ACUR) to Host First Quarter 2012 Financial Results Conference Call on May 2, 2012 More...
• Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Reports First Quarter 2012 Financial Results and Corporate Updates More...
• ViroPharma Incorporated (VPHM) Loses Bid for Order Blocking Generic Vancocin More...
• Icahn and Amylin Pharmaceuticals, Inc. (AMLN) Have May 10 Hearing for Proxy War More...
• Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc. More...
• Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction More...
• Pfizer Consumer Healthcare (PFE) Release: The Advil® Congestion Relief Project Visits St. Louis To Expand Building Space For More Access To Local Family Social Service Program More...
• Ipsen Pursues Its Development in the United States With the Opening of Its New Commercial Headquarters in New Jersey (NJ) More...
• Sanofi (France) (SAN.PA)'s Lemtrada Beats Rebif in MS Face-off More...
• Kythera Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat More...
• AVI BioPharma, Inc. (AVII) to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 American Academy of Neurology Annual Meeting More...
• Repligen Corporation (RGEN) Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy More...
• Ablynx Release: Nanobody for Alzheimer's Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials More...
• American Regent, Inc. Initiates Nationwide Voluntary Recall of Epinephrine Injection, USP, 1:1000, 1 mL Ampules Lot #1395 Due to Discoloration and Small Visible Particles More...
• Novartis AG (NVS) Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing's Disease More...
• Salix Pharmaceuticals, Ltd. (SLXP), Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 More...
• Fish Oil Could be Therapy for Periodontal Disease, University of South Australia Reveals More...
• Botox Ingredient Has Limited Effect on Headaches, Medical College of Wisconsin Study More...
• Does Fatty Food Impact Marital Stress? Ohio State University Medical Center Study More...
• Signs of Early DNA "Aging" in Abused Kids, Duke University Study More...
• Evaluating the First Drug to Show Improvement in Subtype of Autism, Mount Sinai School of Medicine Study More...
• VistaGen Therapeutics, Inc. Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity More...
• Lpath, Inc. Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab More...
• Metabolix, Inc. Awarded Two U.S. Patents for Technology to Produce Biobased Polymers and Industrial Chemicals More...
• BioLineRx Ltd. Announces Extension of Patent for BCM (BL-1040) by USPTO More...
• Marshall Edwards, Inc. (MSHL) Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer More...
• Novartis AG (NVS)'s Gilenya Given Final Approval by UK's Cost Agency More...
• PuraMed BioScience Continues to Build Awareness for LipiGesic(R) M Through Media Campaigns More...
• New Products from Abbott Laboratories (ABT)'s EAS(R) Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals More...
As this firefly comets through the desert, I gain an appreciation for the smallest, most beautiful thing that paints me a picture out of pure light. How wonderful life seems for a moment.
But it’s no firefly. This is actually a newly developed, self-guiding bullet by Sandia National Laboratories. Designed for contemporary guns, this 4-inch smart bullet steers itself through the air, making 30 precision adjustments per second, to strike a laser-targeted spot over a mile away.
Whereas most bullets spiral through the air, Sandia’s bullet flies balanced, like a miniature airplane. Tiny electromagnetic actuators make micro adjustments to tail fins that slice through the air. And as you can see in that almost-inspiring lead photo, in which an onboard LED traces the bullet’s path, the journey is anything but straight. In fact, the flight path can actually over-correct rather than attempt precision calculations at every turn, and still reach a target that’s over half a mile away within an 8-inch range (by comparison, an unguided bullet could miss by as much as 27 feet). And the longer the flight, the more of these approximate adjustments can be made, meaning that the longer the bullet flies, the more accurate it becomes.
Indeed, the bullet’s entire design has a dark brilliance to it, using a bullet’s primary limitation (range) as its strength. But still, did they need to present it so gorgeously? I’ll never look at another light painting the same way again, knowing that a bullet could take the place of any flashlight in the dark.
But it’s no firefly. This is actually a newly developed, self-guiding bullet by Sandia National Laboratories. Designed for contemporary guns, this 4-inch smart bullet steers itself through the air, making 30 precision adjustments per second, to strike a laser-targeted spot over a mile away.
Whereas most bullets spiral through the air, Sandia’s bullet flies balanced, like a miniature airplane. Tiny electromagnetic actuators make micro adjustments to tail fins that slice through the air. And as you can see in that almost-inspiring lead photo, in which an onboard LED traces the bullet’s path, the journey is anything but straight. In fact, the flight path can actually over-correct rather than attempt precision calculations at every turn, and still reach a target that’s over half a mile away within an 8-inch range (by comparison, an unguided bullet could miss by as much as 27 feet). And the longer the flight, the more of these approximate adjustments can be made, meaning that the longer the bullet flies, the more accurate it becomes.
Indeed, the bullet’s entire design has a dark brilliance to it, using a bullet’s primary limitation (range) as its strength. But still, did they need to present it so gorgeously? I’ll never look at another light painting the same way again, knowing that a bullet could take the place of any flashlight in the dark.
• Novartis AG (NVS) Pushes UK Hospitals to Use $1,000 Drug More...
• Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States More...
• Mylan Inc. (MYL) Launches Generic Version of Zyprexa® Tablets More...
• Vertex Pharmaceuticals (MA) (VRTX) Release: INCIVEK™ (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan More...
• Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Olanzapine Tablets More...
• Ikaria Inc.'s LUCASSIN® Approved in Australia More...
• Alimera Sciences (ALIM) Release: ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Says Phase III Data Highlight Safety Profile For BG-12 MS Drug; Stock Rises +Up 2.14(1.70%) @ 1:22PM EDT More...
• Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 More...
• Nordion International Announces Europe-Focused Phase III Clinical Trial for TheraSphere® Liver Cancer Treatment More...
• RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months More...
• Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease More...
• Evidence Behind Autism Drugs May Be Biased, University of Michigan Study More...
• Could Caffeine Help Dry Eye? University of Tokyo School of Medicine Study More...
• How to Look Good on Facebook, University of Twente Study More...
• PURE Bioscience (PURE) Announces Positive Research from University of Arkansas More...
• Advanced Cell Technology Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial More...
• NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor More...
• MediciNova, Inc. Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain More...
• Merck KGaA (MKGAF.PK) Slashes 580 Jobs Amid Swiss HQs Shutdown More...
• Unipharma to Add 44 Jobs in New York More...
• Argos Therapeutics, Inc. Raises $25 Million Series D Financing More...
• miRagen Therapeutics Secures $20 Million Series B Financing More...
• Watson Pharmaceuticals, Inc. (WPI) May Pay $6 Billion Actavis More...
• Bausch & Lomb and ISTA Pharmaceuticals, Inc. (ISTA) Announce Early Termination of Hart-Scott-Rodino Waiting Period More...
• IMS Health (RX) Expands Services in Pharma R&D With Acquisition of DecisionView More...
• US Clinical Laboratories Announces Houston Acquisition More...
• Bayer AG (BAY.F) to Develop Cancer Treatment With Amgen (AMGN) More...
• ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development More...
• Northwest Biotherapeutics (NWBT) and Fraunhofer IZI Announce Milestones Reached More...
• Cerus Corporation (CERS) and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity More...
• Amgen (AMGN) Founding CEO George Rathmann Dies More...
• The New Amgen (AMGN) CEO and the Challenges He Faces, Must Win Investors With Payouts, Deals: Analysts More...
• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments More...
• BioScrip (BIOS) Appoints Hai V. Tran as Senior Vice President, Chief Financial Officer and Treasurer More...
• miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran More...
• Novartis AG (NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump More...
• Alexion Pharmaceuticals Inc. (ALXN) Reports First Quarter 2012 Results More...
• Array BioPharma, Inc. (ARRY) to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012 More...
• Astex Pharmaceuticals (ASTX) to Announce 2012 First Quarter Financial Results on April 30, 2012 More...
• Aegerion Pharmaceuticals, Inc. to Announce First Quarter 2012 Financial Results on Tuesday, May 1 More...
More Earnings Report News
![]()
• The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in NeurogesX, Inc. (NGSX) of Class Action Lawsuit More...
More Legal News
![]()
• Life Technologies (LIFE) to Build Additional $20 Million State of the Art Cell Culture Facility in Scotland More...
• AAIPharma Services Opens New Technology Center More...
• PsiOxus Therapeutics Limited Moves into New Facilities on Milton Park to Accommodate Expansion More...
• Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States More...
• Mylan Inc. (MYL) Launches Generic Version of Zyprexa® Tablets More...
• Vertex Pharmaceuticals (MA) (VRTX) Release: INCIVEK™ (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan More...
• Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Olanzapine Tablets More...
• Ikaria Inc.'s LUCASSIN® Approved in Australia More...
• Alimera Sciences (ALIM) Release: ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Says Phase III Data Highlight Safety Profile For BG-12 MS Drug; Stock Rises +Up 2.14(1.70%) @ 1:22PM EDT More...
• Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 More...
• Nordion International Announces Europe-Focused Phase III Clinical Trial for TheraSphere® Liver Cancer Treatment More...
• RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months More...
• Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease More...
• Evidence Behind Autism Drugs May Be Biased, University of Michigan Study More...
• Could Caffeine Help Dry Eye? University of Tokyo School of Medicine Study More...
• How to Look Good on Facebook, University of Twente Study More...
• PURE Bioscience (PURE) Announces Positive Research from University of Arkansas More...
• Advanced Cell Technology Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial More...
• NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor More...
• MediciNova, Inc. Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain More...
• Merck KGaA (MKGAF.PK) Slashes 580 Jobs Amid Swiss HQs Shutdown More...
• Unipharma to Add 44 Jobs in New York More...
• Argos Therapeutics, Inc. Raises $25 Million Series D Financing More...
• miRagen Therapeutics Secures $20 Million Series B Financing More...
• Watson Pharmaceuticals, Inc. (WPI) May Pay $6 Billion Actavis More...
• Bausch & Lomb and ISTA Pharmaceuticals, Inc. (ISTA) Announce Early Termination of Hart-Scott-Rodino Waiting Period More...
• IMS Health (RX) Expands Services in Pharma R&D With Acquisition of DecisionView More...
• US Clinical Laboratories Announces Houston Acquisition More...
• Bayer AG (BAY.F) to Develop Cancer Treatment With Amgen (AMGN) More...
• ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development More...
• Sandoz, Inc. Enters Local Cameroon Production Partnership to Increase Access to Quality Medicines in Sub-Saharan Africa More...
• Northwest Biotherapeutics (NWBT) and Fraunhofer IZI Announce Milestones Reached More...
• Cerus Corporation (CERS) and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity More...
• Amgen (AMGN) Founding CEO George Rathmann Dies More...
• The New Amgen (AMGN) CEO and the Challenges He Faces, Must Win Investors With Payouts, Deals: Analysts More...
• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments More...
• BioScrip (BIOS) Appoints Hai V. Tran as Senior Vice President, Chief Financial Officer and Treasurer More...
• miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran More...
• Novartis AG (NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump More...
• Alexion Pharmaceuticals Inc. (ALXN) Reports First Quarter 2012 Results More...
• Array BioPharma, Inc. (ARRY) to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012 More...
• Astex Pharmaceuticals (ASTX) to Announce 2012 First Quarter Financial Results on April 30, 2012 More...
• Aegerion Pharmaceuticals, Inc. to Announce First Quarter 2012 Financial Results on Tuesday, May 1 More...
More Earnings Report News
• The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in NeurogesX, Inc. (NGSX) of Class Action Lawsuit More...
More Legal News
• Life Technologies (LIFE) to Build Additional $20 Million State of the Art Cell Culture Facility in Scotland More...
• AAIPharma Services Opens New Technology Center More...
• PsiOxus Therapeutics Limited Moves into New Facilities on Milton Park to Accommodate Expansion More...
Jeremy Grantham's (who runs the value fund manager GMO) quarterly letters are usually masterpieces containing a wealth of market wisdom , and his latest piece is no exception to the rule. The letter is divided into two sections, with the first part analysing the negative impact of "career risk", through multiple channels, on investment performance and the second part covering the current market outlook (which is written by his colleague Ben Inker). To summarise:
1 of 1 File(s)
-A central truth of investing is that professional investor behavior is driven by "career risk" – which forces investors to act with a herd mentality. It explains the significant deviations between stock market performance and remarkably stable GDP growth and growth in the market's "fair value". (Please see the graph below and also note that the deviations ultimately converge back to the GDP growth trend, and over time the stock market does track GDP growth).
-Analysing data since 1882, it is clear that the market is about 19 times more volatile than its underlying fundamental engines – GDP growth and growth in fair value. This volatility arises from the herding, or momentum seeking, behaviour of investors.
-Two-thirds of the value of a stock lies in the expected cash-flows of a stock beyond 20 years, though the stock market often trades as if all the value lies in the immediate future. Ignoring short-term fluctuations to focus on the long-term fundamentals is simply too dangerous for careers.
-A method to survive this bull market irrationality involves; 1) allow a "margin of safety" in your investments – i.e. wait patiently for the fat pitches, 2) stay reasonably diversified, and, 3) never use leverage.
-In investing, "it is simple to see what is necessary but, but not easy to willing or able to do it". In 1998 and 1999, 1100 professional investors (when asked to vote) expected the S&P p/e to revert back to 17 (and stay there) from a then historical high of 35 ( implying a major bear market) but almost all later reassured clients that there was no need to worry and that they should stay invested.
-Therefore, because asset class selection has a critical impact on career risk, the best investment opportunities are likely to be at the asset level than in individual stocks and industries.
-A classic failing of value managers (and poker players) is to get impatient and bet too hard too soon- they have tended to be about 2.5 years too early in major bull markets (a bit shorter for bear markets). However, diversification and a reasonable amount of safety margin has left the pain for clients at just tolerable levels.
-Based on his experience in managing his sister's pension assets since 1968, which has done better than their first institutional asset allocation fund, the two key factors behind the outperformance have been: 1) being able to focus on absolute returns and not being subject to investor constraints, and, 2) the freedom to make big bets when it made sense- like in 1998 to 1999 and 2007.
-Their benchmark-free allocation strategy (which provides more freedom to be less invested when the market was overpriced) has returned 151% since 2001, compared with 72% for their global asset allocation strategy and 25% for the global balanced benchmark.
-Another important indicator of performance is the Sharpe Ratio - which measures how many units of price volatility (risk) an investor has received in the past per unit of return. The global balanced benchmark had a Sharpe Ratio of .25 (four units of volatility per unit of return) , the global asset allocation strategy had a Sharpe Ratio of 0.6 (less than two units of volatility per unit of return) , and the benchmark-free asset allocation strategy had a Sharpe Ratio of 1.1 which implies twice the efficiency of the global asset allocation strategy and four times that of the global balanced benchmark.
-However, clients have typically focussed on the "raw" return and ignored the increased efficiency due to lower volatility. The Sharpe Ratio is one of the few aspects of financial theory which does offer real value to investors, by measuring (albeit in the short-term) the chance of a real loss of money.
-The risk of a benchmark-free asset allocation strategy is underperformance in bull markets, but it mitigates the real risk of investing – a permanent loss of capital. The cardinal rule of investing is not to underperform in bear markets.
Market outlook:
-The big question for investors today is whether to take the bait offered by the Fed - which is to entice investors into risky assets by keeping rates very low and taking government bonds out of the market through quantitative easing.
-Moving into bonds and cash, which are unattractive assets, actually increases the portfolio risk whereas in previous years like 2007, moving away from risky assets lowered portfolio risk.
-Typically they construct their portfolios based on a 7-year time frame for mean reversion to fair value for each asset class, and expect the portfolio to outperform irrespective of when the asset mean reverted over the 7-year period. However, the portfolio you would want to hold today if assets mean reverted immediately versus gradually over 7-years would be very different.
-Today stocks, bonds and cash are all expensive relative to fair value, and if valuations were guaranteed to mean revert gradually over 7-years then it would imply holding equity-heavy portfolios because the risk/return gap between stocks and bonds or cash is wider than normal. However, if mean-reversion happens earlier, then having a heavier weighting in bonds and cash would make sense as bonds and cash have a shorter duration than stocks and their prices would fall by less.
-Because of this peculiarity in current market conditions, they are weighted slightly less in equities than what their 7-year forecasts would imply – 48%-58% for absolute return oriented portfolios. Their bonds holdings are also lower than normal - mainly in Australian and New Zealand government bonds (because of favourable real yield and government policies), and their holdings of cash and "other" assets is higher than normal.
Deep insights and further bolsters the argument in favour of being a contrarian investor and utilising fully the main advantage individual investors have over the professionals (as detailed in his last quarterly letter)– patience! In addition, as suggested in previous letters, holding a well diversified portfolio covering EM equities (China, India, Brazil, and select others) , US energy and global natural resources stocks, high quality multinationals, EM US$ and local currency bonds, US credit funds, gold and cash would be a appropriate strategy in the currently peculiar environment. I personally hold the view that the 7-year mean reversion will commence at least after 2014 due to QE polices by global central banks, implying that one cannot get too bearish.
A recent note from the Goldman Sachs Strategy team puts it very well:
"While the economic backdrop, neutral valuations, and moderate geopolitical and economic risks favour equities in our opinion, we also recognize that investing in equities entails volatility. As an asset class with 15% annual volatility, it is typical for equities to decline by 5% or more about 3 times a year and 10% or more about once a year, on average. So to capture the upward trend in equities, an investor has to tolerate the frequent downdrafts. The latest non-farm payroll and heightened concerns about peripheral Europe might well result in one of these downdrafts; in fact, our very short-term momentum signals have turned negative. But as investors - rather than traders - we recommend staying long equities. For those who are underinvested, we recommend using downdrafts as opportunities to build equity positions."
And for those who still doubt the dependency of markets on QE programmes, I present a chart from the bond fund manager Jeffrey Gundlach. The likelihood of further QE remains high!
A Yoga Tip:
The spine plays an important role in Yoga and Ayurveda, and blockage/compression/tension in the spine can negatively impact the nervous system and blood flow. Maintaining a healthy and supple spine is therefore critical for good health and there are two simple Yoga asanas (postures) that I do regularly and have found to be very effective (have suggested them to a few other people who have found them to be very helpful):
-Lie on the floor (or on a hard bed) on the stomach, with legs together, raise your head and cup your chin with your palms, keeping your elbows together and perpendicular to the ground. Lie in this position for 5 minutes (or more) – you can watch TV while you do this if you would like! The best time is morning (after waking) and in the evening before sleeping. This posture gently stretches the whole spine and is great for lower back aches and neck pain or stiffness. A variation is folding one leg at a time gently , bringing your heel as close to the buttocks as possible, for a minute or so and then folding both legs together. After finishing, curl into child's pose (buttocks on heels, forehead on the floor and arms stretched out alongside the head) for a few minutes – this is a reversal of the posture.
-Lie on your back on the edge of your bed, with your head over the side and your shoulders just over the edge, for a few minutes. You can then bring your arms up alongside your head and stretch gently by interlocking the fingers. After completion slide back on the bed (make sure you don't jerk your neck!). This posture is especially beneficial for neck stiffness and pain and is based on the simple principle of reversal as one spends most of the day with the spine bent forward.
Generally speaking, if you have spinal issues any forward spending postures are usually prohibited. Back bending and spinal twisting postures are usually beneficial. And don't sit for more than 30 minutes at a stretch, take a walk for a few minutes in-between. Of course, if you have had spinal surgery please consult our doctor before trying these postures. More on spinal health in the next newsletter!
1 of 1 File(s)
Apple Inc ( NASDAQ: AAPL ) the most valuable company on earth, has delivered a smashing quarterly earnings of $12.30 per share blowing away the expectation of $10.04 a share from analysts. Also, Skeptics has doubted about lag in iPhone sales but the numbers also topped that expectations.
Company's stock has corrected more than 12 % from its high due to rumors about earnings disappointment, but Apple Inc has once again convinced wall street that it may not be affected by economic uncertainty.
Stock jumped more than 10 % in premarket trading may be stand strong through out the trading session.
Find below the detailed earnings:
"Apple once again surprises on the upside despite expectations that iPhone sales would lag," Michael Yoshikami, CEO of YCMNET Advisors told Reuters. "When you have a strong rally in a stock it often sells off for no better reason than uncertainty—I think you're going to see the naysayers go away."
The tech giant reported fiscal second-quarter earnings of $12.30 a share on sales of $39.2 billion. The company was seen earning $10.04 a share on revenue of $36.8 billion, according to a consensus estimate from Thomson Reuters.
In addition, the company said it sold 35.1 million iPhones in the last quarter, easily surpassing estimates of approximately 30.5 million units.
“The bigger takeaway is that Apple is becoming a fantastic international growth story and it’s difficult to do proper channel checks just with the U.S.,” said Peter Misek, equity analyst at Jefferies. “Estimates are now probably going to be tweaked upwards.”
Earlier today, Jefferies lowered its iPhone sales estimates to between 28 million to 30 million, based on declining activation numbers from major carriers AT&T and Verizon
Shares of the iPad maker jumped more than 5 percent in after-hours trading. The stock fell 2 percent to close at $560.28 in the regular session. The stock has tumbled 13 percent since hitting its all-time high of $644 a share two weeks ago.
"These stocks don't trade straight up or straight down," said Shaw Wu, senior technology analyst at Sterne Agee, adding that the new iPhone 5 and the smartphone's strength in China could drive the stock to $750.
Meanwhile, Apple's product suppliers including Broadcom, Avaco Technologies and Qualcomm also rallied in after-hours trading following the announcement.
• Amylin Pharmaceuticals, Inc. (AMLN) Soars as Potential Bidding War Begins More...
• Nestle SA to Buy Pfizer Inc. (PFE)'s Infant Nutrition Unit for $11.9 Billion More...
• AstraZeneca PLC (AZN) to Acquire Ardea Biosciences, Inc. for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout More...
• Nabi Biopharmaceuticals (NABI) Merges With Biota Holdings Limited (BTA.AX) to Create a $250 Million Group; Biota to Move to the US More...
• Roche (RHHBY) Starts Talking to Illumina, Inc. (ILMN) Rivals More...
• OLIGOMERIX Completes $2 Million Series A Financing More...
• OrbiMed Launches $222 Million Fund Focused on Israel Life Sciences More...
• Merck & Co., Inc. (MRK) Invests $150 Million In R&D at Jamia Millia Islamic University More...
• Israeli High Tech Firms Raise $483 Million in Q1 from VCs More...
• AMAG Pharmaceuticals, Inc. (AMAG) Gets Initial EU Nod, Potentially Bagging a $30 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKDG.DE) More...
• Biovest International, Inc. and US Army Enter into Collaborative Agreement to Develop Novel Bioreactor Systems as Platform Technology for Production of Anti-Viral Vaccines and Drugs More...
• Johnson & Johnson (JNJ) Open to Expanding Hepatitis C Cooperation WithVertex Pharmaceuticals (MA) (VRTX) More...
• Pressure BioSciences, Inc. (BBII) and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services More...
• Ezose Sciences, Inc. and Hirosaki University to Collaborate in Glycomics Research to Find New Cancer Biomarkers More...
• Kolltan Pharmaceuticals Inc. Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer More...
• Quintiles Transnational Corp. Names Tom Pike CEO More...
• PAREXEL International (PRXL) Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award More...
• Alnylam Pharmaceuticals (ALNY) Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board More...
• Compugen Ltd. (CGEN) First Quarter 2012 Conference Call Scheduled for Tuesday, May 1, 2012 at 10:00 AM EST More...
• Association of Clinical Research Organizations (ACRO) Testifies Before FDA on Clinical Trial Modernization More...
• Novartis AG (NVS) Plans $550 Million Manufacturing Plant in Switzerland More...
• Ultragenyx Relocates Company Headquarters to Support Operational Expansion More...
• QUMAS Opens New Asian Office in Singapore More...
• FDA Pushes Back Bowel Drug Review: Ironwood Pharmaceuticals, Forest Laboratories, Inc. (FRX) More...
• AMAG Pharmaceuticals, Inc. (AMAG) Gets Initial EU Nod, Potentially Bagging a $30 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKDG.DE) More...
• AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Say FORXIGA Gets Positive CHMP Opinion in EU More...
• Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Further Opinion on Glybera® Marketing Authorization Application More...
• Achillion Pharmaceuticals, Inc. Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C More...
• PolyMedix Inc. (PYMX.OB) Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic More...
• Celsion Corporation (CLN) Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer More...
• Keryx Biopharmaceuticals (KERX) Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co. More...
• Medgenics, Inc. Files for U.S. Orphan Drug Designation for INFRADURE for the Treatment of Hepatitis D More...
• Depression Linked to Higher Odds for Poor Leg Circulation, University of California, San Francisco (UCSF) Study More...
• "Ice Cream Headaches" Might Offer Clues to Migraines, Harvard Medical School Study More...
• Soda Elevates and Coffee Lowers Stroke Risk, Harvard University andCleveland Clinic's Wellness Institute Study More...
• Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned, Center for Clinical Intervention Research Study More...
• BioTime (BTX) Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells More...
• Regulus Therapeutics, Inc. Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate More...
• Spectrum Pharmaceuticals, Inc. (SPPI) Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® More...
• Nestle SA to Buy Pfizer Inc. (PFE)'s Infant Nutrition Unit for $11.9 Billion More...
• AstraZeneca PLC (AZN) to Acquire Ardea Biosciences, Inc. for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout More...
• Nabi Biopharmaceuticals (NABI) Merges With Biota Holdings Limited (BTA.AX) to Create a $250 Million Group; Biota to Move to the US More...
• Roche (RHHBY) Starts Talking to Illumina, Inc. (ILMN) Rivals More...
• OLIGOMERIX Completes $2 Million Series A Financing More...
• OrbiMed Launches $222 Million Fund Focused on Israel Life Sciences More...
• Merck & Co., Inc. (MRK) Invests $150 Million In R&D at Jamia Millia Islamic University More...
• Israeli High Tech Firms Raise $483 Million in Q1 from VCs More...
• AMAG Pharmaceuticals, Inc. (AMAG) Gets Initial EU Nod, Potentially Bagging a $30 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKDG.DE) More...
• Biovest International, Inc. and US Army Enter into Collaborative Agreement to Develop Novel Bioreactor Systems as Platform Technology for Production of Anti-Viral Vaccines and Drugs More...
• Johnson & Johnson (JNJ) Open to Expanding Hepatitis C Cooperation WithVertex Pharmaceuticals (MA) (VRTX) More...
• Pressure BioSciences, Inc. (BBII) and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services More...
• Ezose Sciences, Inc. and Hirosaki University to Collaborate in Glycomics Research to Find New Cancer Biomarkers More...
• Kolltan Pharmaceuticals Inc. Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer More...
• Quintiles Transnational Corp. Names Tom Pike CEO More...
• PAREXEL International (PRXL) Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award More...
• Alnylam Pharmaceuticals (ALNY) Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board More...
• Compugen Ltd. (CGEN) First Quarter 2012 Conference Call Scheduled for Tuesday, May 1, 2012 at 10:00 AM EST More...
• Association of Clinical Research Organizations (ACRO) Testifies Before FDA on Clinical Trial Modernization More...
• Novartis AG (NVS) Plans $550 Million Manufacturing Plant in Switzerland More...
• Ultragenyx Relocates Company Headquarters to Support Operational Expansion More...
• QUMAS Opens New Asian Office in Singapore More...
• FDA Pushes Back Bowel Drug Review: Ironwood Pharmaceuticals, Forest Laboratories, Inc. (FRX) More...
• AMAG Pharmaceuticals, Inc. (AMAG) Gets Initial EU Nod, Potentially Bagging a $30 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKDG.DE) More...
• AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Say FORXIGA Gets Positive CHMP Opinion in EU More...
• Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Further Opinion on Glybera® Marketing Authorization Application More...
• Achillion Pharmaceuticals, Inc. Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C More...
• PolyMedix Inc. (PYMX.OB) Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic More...
• Celsion Corporation (CLN) Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer More...
• Keryx Biopharmaceuticals (KERX) Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co. More...
• Medgenics, Inc. Files for U.S. Orphan Drug Designation for INFRADURE for the Treatment of Hepatitis D More...
• Depression Linked to Higher Odds for Poor Leg Circulation, University of California, San Francisco (UCSF) Study More...
• "Ice Cream Headaches" Might Offer Clues to Migraines, Harvard Medical School Study More...
• Soda Elevates and Coffee Lowers Stroke Risk, Harvard University andCleveland Clinic's Wellness Institute Study More...
• Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned, Center for Clinical Intervention Research Study More...
• BioTime (BTX) Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells More...
• Regulus Therapeutics, Inc. Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate More...
• Spectrum Pharmaceuticals, Inc. (SPPI) Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® More...
